Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma? by Cooper, R et al.
Glucose transporter-1 (GLUT-1): a potential marker of prognosis
in rectal carcinoma?
R Cooper*,1, S Sariog ˘lu
2,SS o ¨kmen
3,MF u ¨zu ¨n
3,AK u ¨peliog ˘lu
2, H Valentine
5,I BG o ¨rken
1, R Airley
4 and C West
5
1Department of Radiation Oncology, Dokuz Eylu ¨l University Medical School, Inciraltu, Izmir 35340, Turkey;
2Department of General Surgery, Dokuz Eylu ¨l
University Medical School, Izmir 35340, Turkey;
3Department of Pathology, Dokuz Eylu ¨l University Medical School, Izmir 35340, Turkey;
4Tumour
Metabolism and Therapeutics Group, School of Pharmacy and Chemistry, John Moores University, Liverpool L3 3AF, UK;
5Academic Department of
Radiation Oncology, Christie Hospital, Manchester M20 4BX, UK
The aim of the study is to evaluate the pattern and level of expression of glucose transporter-1 (GLUT-1) in rectal carcinoma in
relation to outcome as a potential surrogate marker of tumour hypoxia. Formalin-fixed tumour sections from 43 patients with rectal
carcinoma, who had undergone radical resection with curative intent, were immunohistochemically stained for GLUT-1. A mean of
three sections per tumour (range 1–12) were examined. Each section was semiquantitatively scored; 0, no staining; 1, o10%; 2,
10–50%; 3, 450% and a score given for the whole section, the superficial (luminal) and deep (mural) part of the tumour. Staining
was seen in 70% of tumours. Increased staining was noted adjacent to necrosis and ulceration. A diffuse and patchy pattern of
staining, with and without colocalisation to necrosis was seen. Patients with high GLUT-1-expressing tumours (score 3 vs 0–2) had a
significantly poorer overall survival (P¼0.041), which was associated with poorer metastasis-free survival with no difference in local
control. No significant correlation was seen with other prognostic factors. There was a strong correlation between the score for the
superficial and deep parts of the tumour (r¼0.81), but a significant relationship with outcome was only found in the deep part
(P¼0.003 vs P¼0.46). In conclusion, increased GLUT-1 expression in rectal tumours was an adverse prognostic factor and is worth
further evaluation as a predictive marker of response to therapy.
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The presence of hypoxia in tumours is known to lead to resistance
to radiotherapy and chemotherapy and is associated with a more
aggressive phenotype with an increased propensity for metastases
(Hockel et al, 1996; Brown et al, 1998; Dachs et al, 1998). This
latter finding is thought to be related to the increased expression of
a number of proteins acting through the HIF-1 pathway, which
allows tumour cells to survive the harsh tumour microenviroment
(Maxwell et al, 1997; Semenza, 2000). The glucose transporter-1
(Glut-1) is one of the proteins upregulated in hypoxic conditions.
Tumours show increased uptake of glucose compared to normal
tissue (Isslbacher, 1972), a response mediated by a number of
facilitative glucose transporters located in the cell membrane
(Zhang et al, 1999). Glut-1 is one of this family of facilitative
glucose transporters. It is expressed variably in normal tissue
(Mueckler et al, 1985) and is responsible for the passive transport
of glucose across the cell membrane (Chen et al, 2001). The
function and expression of Glut-1 is regulated by a number of
physiological and pathophysiological conditions (Zhang et al,
1999). In the tumour microenvironment, hypoxia results in
increased transcription of the Glut-1 gene, mediated through
HIF-1, and reduction in oxidative phosphorylation, in the absence
of hypoxia, leads to increased stabilisation of the Glut-1 mRNA
(Behrooz et al, 1997). Glucose transporter-1 is overexpressed in
several different tumour types (Younes et al, 1996). In addition,
increased expression has been shown to correlate with a poor
prognosis in a variety of tumours (Younes et al, 1997; Haber et al,
1998; Airley et al, 2001; Cantuaria et al, 2001). More recently, Glut-
1 expression has been shown to correlate with the level of tumour
hypoxia in carcinoma of the cervix measured using either
Eppendorf needle electrodes (Airley et al, 2001) or pimonidazole
staining (Airley et al, 2003). Therefore, the level of Glut-1
expression might be a suitable surrogate or intrinsic marker of
hypoxia, which could be measured simply and inexpensively as
part of the routine histological assessment of tumours.
Little is known about the oxygenation of rectal tumours;
however, it is likely that hypoxia plays a significant part in
determining outcome (Haustermans et al, 2000; Wendling et al,
1984). Furthermore, determination of the level of hypoxia might be
important for selecting appropriate preoperative radiotherapy or
chemoradiotherapy regimes or determining which patients are
more likely to develop distant metastases and therefore require
systemic therapy. In this study, we report for the first time the level
and pattern of expression of Glut-1, as a potential endogenous
marker of hypoxia, in rectal carcinoma and relate the level of
expression to outcome.
PATIENTS AND METHODS
Patients
The study was retrospective. Formalin-fixed tumour sections from
43 consecutive patients (29 male, 14 female) with rectal carcinoma
who had undergone curative intent treatment at a single institution Received 7 March 2003; revised 19 June 2003; accepted 24 June 2003
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sections from all available tissue blocks were taken (median 2;
range 1–12). The median age was 56 years (range 21–80). All
patients underwent radical surgery with a curative intent. Only one
patient underwent an R1 resection (microscopic residual disease),
the remaining 42 underwent an R0 resection (no residual disease).
Pathological tumour stages are summarised in Table 1. Adjuvant
therapy was either preoperative radiotherapy/chemoradiotherapy
(n¼6), postoperative radiotherapy/chemoradiotherapy (n¼18)
or postoperative chemotherapy alone (n¼3). Pre- and post-
operative radiotherapy/chemoradiotherapy was administered in an
outpatient setting. Patients undergoing radiotherapy were treated
with 6 MV or
60Co gamma radiation. A four-field box technique
was used extending from the junction of L4/L5 to the bottom of the
obturator foramina and 1cm beyond the lateral pelvic side walls.
The field extended from the most posterior aspect of the sacrum to
the posterior part of the pubic bone. The prescribed dose, specified
to an appropriate isodose envelope, was 45Gy in 25 fractions
(1.8Gy per fraction) given once daily 5 days per week. Concurrent
chemotherapy was administered as a continuous infusion of
225mg/m
 2 5-fluorouracil. Three patients received adjuvant
chemotherapy consisting of 5-fluorouracil and folinic acid using
the de Gramont regimen. The median follow-up for all patients was
46 months (range 8–102 months) and 49 months (range 30–102
months) for surviving patients.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tumour sections (5mm thick)
were placed on poly-L-lysine-coated slides. Sections were dewaxed
in xylene and rehydrated using a series of ethanol solutions of
increasing dilution. Staining was carried out using the Envision
Plus horseradish peroxidase (HRP) kit (DAKO, UK). First, an
endogenous peroxidase supplied with the kit was applied for 5min
at room temperature. The samples were then washed, incubated in
10% casein at room temperature for 15min and then washed
again. A 1:100 (10mgml
 1 protein) concentration of affinity-pure
rabbit anti-human Glut-1 (Alpha Diagnostic International, TX,
USA) was applied and the sections were incubated for 1h at 37
oC.
A rabbit IgG fraction (DAKO) at an identical protein concentration
was used as a negative control. Following washing, the secondary
antibody (goat anti-rabbit/HRP) was applied to the sections for
30min at room temperature. A substrate–chromogen solution
containing 3.30-diaminobenzidine in a buffered substrate solution,
supplied in the kit, was applied at room temperature for 7min.
After rinsing in water, the slides were counterstained with Gills
haematoxylin, dehydrated and mounted. The batch to batch
variation was excluded by running sections from the same biopsy
through more than one batch, and running one biopsy section
through all the batches.
Scoring method
Glucose transporter-1 expression in tumour cells was evaluated
using a semiquantitative scoring method: score 0¼absence of
immunostaining; score 1¼1–10% of cells stained; score 2¼10–
50% of cells stained; and score 3¼450% of cells stained. No
account was taken of the intensity of staining, and ulcerated or
necrotic areas were excluded from the evaluation. For each tumour
section, three areas were scored: a general score for the whole
tumour section, a score for the superficial part of the tumour
(approximately nearest one-third from the luminal surface) and a
score for the deep part (approximately deepest one-third from the
luminal surface). Intraobserver reliability was tested by the same
pathologist re-evaluating 20 slides chosen at random after a 4-week
gap.
Statistical analysis
Previous studies have analysed Glut-1 expression as either positive
(score 1–3) vs negative (score 0) or strongly positive (score 3) vs
the rest (score (0–2) (Younes et al, 1997; Haber et al, 1998; Airley
et al, 2001). It was therefore decided to analyse our patients using
these two categories. Correlations between tumour characteristics
and the expression of Glut-1 were obtained using a two-tailed
Spearman’s rank correlation and Fisher’s exact test. Survival
analysis was by the Kaplan–Meier method, and prognostic factors
were assessed by log-rank statistics. Analyses were carried out for
overall, metastasis-free and local recurrence-free survival. Bivariate
analyses were used to test for the independence from other
potential prognostic factors including T stage, nodal stage and
tumour size.
RESULTS
Expression of GLUT-1
Glucose transporter-1 expression was only observed as membra-
nous staining in tumour cells. Erythrocytes within blood vessels
were also seen to stain strongly for Glut-1, which served as an
internal control. Perinecrotic and periulcerative areas stained
strongly. Two patterns of staining were observed, a focal pattern
and a more diffuse staining. Although staining was increased
around necrotic areas, the patchy staining pattern was not
consistently localised to necrosis. In addition, more cells were
positive in the deeper portion of the tumour compared to the
superfical luminal part. Normal cells and tumour stroma did not
stain for Glut-1. There was a significant correlation between the
first and the second score for the general (r¼0.87, Po0.0001),
superficial (r¼0.59 P¼0.03) and deep (r¼0.82, Po0.0001) parts
of the tumour. Figure 1 illustrates sections that were scored 1,2
and 3.
Distribution of patients according to GLUT-1 expression
Of the 43 cases examined, 70% expressed Glut-1. The distribution
of scores is shown in Table 2. There was a strong correlation
between the overall tumour score and the scores for the deep
Table 1 Summary of patient and tumour characteristics
Characteristic
Age (years)
Median 57
Range 21–80
T stage
T2 9
T3 29
T4 5
Nodal status
Negative 27
Positive 16
Tumour size (pathological)
Median (cm) 5
Range (cm) 2–11
o5cm 19
X5cm 24
Grade
11 0
22 4
33
Not classified 6
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the tumour.
Correlation of GLUT-1 expression in relation to clinical
factors
The distribution of Glut-1 expression according to Duke’s stage
and nodal status is shown in Table 3. There was no correlation
between the degree of Glut-1 immunostaining and tumour stage
(r¼ 0.047, P¼0.77). The patients were also grouped according to
the presence or absence of nodal metastasis; however, there was no
significant difference in the metastasis status of patients whose
tumours showed negative (score 0) or positive (scores 1–3) Glut-1
staining (P¼0.52, Fisher’s exact test). Likewise, there was no
significant difference in the metastasis status of patients whose
tumours had weak (score 0–2) or heavy (score 3) Glut-1 staining
(P¼0.30, Fisher’s exact test). Furthermore, there was no
significant association between Glut-1 expression and either
tumour grade (r¼0.10, P¼0.58) or pathological size (r¼ 0.02,
P¼0.89).
Relationship between Glut-1 expression and outcome
To examine whether the group of patients studied had similar
characteristics to larger groups of patients with rectal cancer, we
analysed the relationship between treatment outcome and
established clinical prognostic factors (tumour stage, nodal status
and tumour size). As expected, advanced stage was a significant
adverse prognostic factor (P¼0.023). In addition, the 5-year
actuarial survival was higher for patients with node negative (89%)
vs positive (56%) tumours (P¼0.009), and tumours that were
pathologically o5cm (89%) rather than X5cm (67%) in diameter
(P¼0.06). Grade was a borderline significant prognostic factor for
survival (P¼0.06).
There was no significant difference in the overall survival of
patients with Glut-1 positive (score 1–3) vs negative (score 0)
tumours (71 vs 92% at 5 years; P¼0.17). There was, however, a
significant difference in overall survival for patients with strongly
positive tumours (score 3) compared to those with a score of 0–2
(33% vs 80%, respectively; P¼0.041). Survival curves are shown in
Figure 2. Strong Glut-1 expression in tumours appeared to be
associated with a poor metastasis-free survival (Figure 3) rather
than local control (Figure 4).
Bivariate analyses were performed to test for the independence
from tumour stage, nodal status and tumour size. Glucose
transporter-1 expression remained a significant prognostic
factor for overall survival after allowing for tumour stage
(P¼0.0052) and tumour size (P¼0.05), but not nodal status
(P¼0.16).
Figure 1 (A) Score 1. Less than 10% of the cells are stained by anti-
Glut-1 (magnification  10). (B) Score 2. Between 10 and 50% of the cells
are stained with Glut-1. Strong membranous staining is seen adjacent to an
area of necosis. (magnification  20). (C) Score 3. More than 50% of cells
are stained with Glut-1 at the invasive border. (magnification  20)
Table 2 Distribution of scores
Score 0 1 2 3
Patients (number) 30% (13) 42% (18) 21% (9) 7% (3)
Table 3 Distribution of scores by Duke’s stage and nodal status
Score 0 1 2 3
Stage B 7 11 8 1
Stage C 6 7 1 2
Node negative 8 10 8 1
Node positive 5 8 1 2
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tumour
Scores from the deep part of the tumour were also prognostic for
overall survival (82 vs 25% actuarial survival at 5 years for score
0–2 vs score 3, respectively; P¼0.003). However, the Glut-1
expression of the superficial part of the tumour was not prognostic
for survival (actuarial survival at 5 years 78 vs 50%, P¼0.46 for
score 0–2 vs score 3, respectively).
Independence of Glut-1 staining to known prognostic
factors
In order to assess the degree of Glut-1 staining as an independent
prognostic marker, all factors that had been significant for overall
survival on log-rank univariate analysis (tumour stage, nodal
status, strongly positive vs the rest for the whole tumour section
and the deep part of the tumour) were included in a multivariate
Cox regression analysis. The only factor that was prognostic for
survival was the presence of Glut-1 staining in the deep portion of
the tumour (P¼0.013).
DISCUSSION
The presence of hypoxia in tumours has been shown to correlate
with resistance to therapy and reduced survival. Therefore,
pretreatment assessment of tumour hypoxia might enable predic-
tion of patients likely to have a poor outcome, and who would be
suitable for hypoxia-modifying treatment. Polarographic needle
electrodes have been used to give a quantitative, pretreatment
measurement of tumour hypoxia that correlates with outcome for
patients with carcinoma of the cervix (Hockel et al, 1996; Fyles
et al, 1998), head and neck (Nordsmark et al, 1996; Brizel et al,
1997) and soft tissue sarcoma (Brizel et al, 1996). However, the
method is invasive and limited to accessible tumours greater than
2cm in diameter. Furthermore, any measurement will also include
areas of necrosis that can bias the results to falsely low values. An
alternative method is the immunohistochemical assessment of
bound nitroimadazoles, such as pimonidazole, injected prior to
biopsy (Kennedy et al, 1997; Nordsmark et al, 2001). This requires
an added intervention and, as yet, there are only limited data on
their relationship with treatment outcome. This has prompted a
number of groups to examine potential endogenous markers of
hypoxia, which include proteins that are upregulated under
hypoxia. The transcription factor HIF-1a has been the most widely
studied potential endogenous marker of hypoxia (Aebersold et al,
2001; Haugland et al, 2002; Janssen et al, 2002; Koukourakis et al,
2002), along with its downstream proteins such as carbonic
anhydrase IX (CAIX) (Giatromanolaki et al, 2001; Koukourakis
et al, 2001; Loncaster et al, 2001), vascular endothelial growth
factor (Loncaster et al, 2000; Koukourakis et al, 2002) and Glut-1
(Airley et al, 2001, 2003). The advantage of using intrinsic markers
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Figure 2 Overall survival for (A) score 0 (negative) vs 1–3 (positive)
and (B) score 0–2 (negative) vs 3 (positive).
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Figure 3 Metastasis-free survival for (A) score 0 (negative) vs 1–3
(positive) and (B) score 0–2 (negative) vs 3 (positive).
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potentially applied to a wide variety of solid tumour types.
In the present study, we examined the pattern and extent of
Glut-1 expression in adenocarcinoma of the rectum as a potential
endogenous marker of hypoxia. A total of 70% of tumours
expressed Glut-1 to a varying degree. Glucose transporter-1
expression was seen to localise around areas of necrosis and
ulceration, while little staining was seen in stromal or normal
tissue. In general, two patterns of staining were observed, diffuse
and patchy, the latter showing both colocalisation with necrosis
and non-necrotic areas. Other studies have reported similar
patterns of staining (Haber et al, 1998; Airley et al, 2001). In
addition, two recent studies have shown that the levels of Glut-1
expression in carcinoma of the cervix correlates with the level of
tumour hypoxia measured using either polarographic needle
electrodes (Airley et al, 2001) or pimonidazole staining (Airley
et al, 2002). In the former study, the strongest correlation was seen
with the most hypoxic fraction of polarographic needle electrode
measurements, leading to the suggestion that Glut-1 scores might
represent the level of chronic or diffusion-limited hypoxia, while in
the second study, there was a good, but not exact, colocalisation of
pimonidazole staining and Glut-1 expression. Taken together,
these findings suggest a link between hypoxia and Glut-1
expression in human carcinoma of the cervix. However, several
factors could reduce the usefulness of Glut-1 as a hypoxic marker
and explain the diffuse pattern of staining observed in some of the
tumours. Glucose transporter-1 expression is known to be
stimulated by a number of other stimuli including growth factors,
thyroid hormone, alkaline pH and oncogenic transformation (Flier
et al, 1987; Hakimian et al, 1991; Kuruvilla et al, 1991).
Furthermore, it is dually controlled by both hypoxia and reduced
oxidative phosphorylation in the absence of hypoxia (Behrooz et al,
1997). Chronic hypoxia leads to increased production of Glut-1
that is mediated via the transcription factor HIF-1. Although it was
previously thought that HIF-1 was only stabilised under hypoxia, it
is now known to be constitutively expressed in some tumours due
to genetic alterations occurring during malignant transformation
(Jiang et al, 1997; Feldser et al, 1999; Zhong et al, 2000). This might
therefore explain the diffuse pattern of staining and the patchy
noncolocalisation with necrosis observed in some of the tumours
in the present study.
In order to exploit the measurement of Glut-1 expression as a
marker of hypoxia in different types of tumours, there is a need to
demonstrate that the marker can provide prognostic information
in each tumour type of interest. Previous studies have shown a
relationship between Glut-1 expression and overall survival in
colon cancer (Haber et al, 1998) and lung cancer (Younes et al,
1997), and disease-free survival in ovarian cancer (Cantuaria et al,
2001). In addition, a significant association between Glut-1
expression and metastasis-free survival, but not disease-free
survival or local recurrence, has been reported in patients with
cervical carcinoma (Airley et al, 2001). In the present study, we
were able to show in rectal cancers that strong expression of Glut-1
(450% of tumour cells) was a significant prognostic factor for
overall survival independent of tumour stage and tumour size, and
on multivariate analysis the presence of strong staining in the deep
part of the tumour was the only significant factor for overall
survival. We also observed a nonsignificant relationship with
metastases-free survival, but not local recurrence-free survival, for
the presence of staining (1–3) vs non (0). However, larger
numbers of patients would be required to confirm this.
It is of interest that in the study of Airley et al (2001), where
Glut-1 expression was prognostic for metastasis-free survival, but
not overall or local recurrence-free survival, patients with cervical
carcinoma were treated with radiotherapy. In our study, patients
were predominantly treated with surgery, and Glut-1 was
predictive for overall and metastasis-free survival but again not
local recurrence-free survival. It might be that Glut-1 expression
reflects more severe and longer duration hypoxia, especially as in
our study intense staining (score 3) showed the best correlation
with outcome and heavy staining is more indicative of de novo
Glut-1 synthesis which only occurs after prolonged hypoxia (Shetty
et al, 1992; Behrooz et al, 1997). This in turn might be more
reflective of the tumours propensity to form distant metastases,
associated with hypoxia rather than resistance to radiotherapy and
is consistent with previous experimental and clinical data (Fyles
et al, 2002).
We found no significant relationship between the expression of
Glut-1 in tumours and the accepted clinical prognostic factors of
tumour stage, depth of invasion (T stage), nodal status, tumour
size and grade of differentiation. In contrast, a previous study in
patients with mainly colon cancer showed that extensive staining
(450% of cells) for Glut-1 correlated significantly with the
presence of nodal metastases (Haber et al, 1998). Similarly, no
consistent picture has emerged for any relationships between
clinical prognostic factors and the level of tumour hypoxia
measured using polarographic needle electrodes (Hockel et al,
1996; Nordsmark et al, 1996; Pitson et al, 2001). The fact that no
correlation was found in our study might reflect the low number of
patients included and/or the inhomogeneous treatment given.
However, the lack of association and the fact that only strong
staining in the deep part of the tumour was a significant factor for
overall survival on Cox regression analysis suggests that Glut-1
expression in rectal tumours might give additional information
over and above that provided by the established clinical prognostic
factors. Studies on a larger group of patients are required to clarify
this issue.
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Figure 4 Local recurrence-free survival for (A) score 0 (negative) vs
1–3 (positive) and (B) score 0–2 (negative) vs 3 (positive).
Glut-1 expression in rectal cancer
R Cooper et al
874
British Journal of Cancer (2003) 89(5), 870–876 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yOf interest in our study was the finding that more cells were seen
to express Glut-1 in the deeper compared to the superficial
(corresponding with the luminal surface) parts of tumours. In
addition, no relationship was found between patient outcome and
Glut-1 expression in the superficial part of the tumours. The latter
observation is difficult to interpret because of the lack of published
data on the oxygenation status of rectal tumours. However, the
data do highlight the potential problem of intratumour hetero-
geneity and the need to take multiple biopsies from different parts
of rectal tumours. Taking a mean of three biopsies per patient, as
used in our study, is recommended for other studies in this area.
In the results presented here, Glut-1 was expressed in two-thirds
of the rectal tumours examined, and high expression was
associated with a poor treatment outcome. In addition to Glut-1,
several potential endogenous markers of hypoxia are currently
under investigation including HIF-1a, HIF-2a, CAIX and VEGF.
Studies suggest that different levels and/or durations of tumour
hypoxia are required to upregulate each protein (Giatromanolaki
et al, 2001; Olive et al, 2001). It is possible, therefore, that a
combination of markers might be required to fully evaluate
hypoxia within a given tumour type. Furthermore, several studies
have shown that combining protein expression with other factors,
such as the level of vascularity, improves the definition of patient
groups with differing prognoses (Koukourakis et al, 2001, 2002).
This is the first study of Glut-1 expression in purely rectal
carcinoma. Rectal cancer is an interesting area as preoperative
radiotherapy or chemoradiotherapy is being increasingly used as
part of the treatment. Furthermore, there is still debate as to which
node-negative patients should receive adjuvant chemotherapy. As
several different regimens are being used, a better understanding
of the individual tumour microenvironment might enable a more
rational application of these therapies along with the incorporation
of hypoxia-modifying treatments for those patients with hypoxic
tumours.
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